Floxapen 250 mg inj./inf. sol. (pwdr.) i.v./i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

floxapen 250 mg inj./inf. sol. (pwdr.) i.v./i.m. vial

eugia pharma (malta) ltd. - flucloxacillin sodium monohydrate - eq. flucloxacillin 250 mg - powder for solution for injection/infusion - 250 mg - flucloxacillin 250 mg - flucloxacillin

Floxapen 500 mg inj./inf. sol. (pwdr.) i.v./i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

floxapen 500 mg inj./inf. sol. (pwdr.) i.v./i.m. vial

eugia pharma (malta) ltd. - flucloxacillin sodium monohydrate - eq. flucloxacillin 500 mg - powder for solution for injection/infusion - 500 mg - flucloxacillin 500 mg - flucloxacillin

Floxapen 1 g inj./inf. sol. (pwdr.) i.v./i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

floxapen 1 g inj./inf. sol. (pwdr.) i.v./i.m. vial

eugia pharma (malta) ltd. - flucloxacillin sodium monohydrate - eq. flucloxacillin 1 g - powder for solution for injection/infusion - 1 g - flucloxacillin sodium monohydrate - flucloxacillin

Floxapen 2 g inj./inf. sol. (pwdr.) i.v./i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

floxapen 2 g inj./inf. sol. (pwdr.) i.v./i.m. vial

eugia pharma (malta) ltd. - flucloxacillin sodium monohydrate 2176 mg - eq. flucloxacillin 2000 mg - powder for solution for injection/infusion - 2 g - flucloxacillin sodium monohydrate 2176 mg - flucloxacillin

FULVESTRANT EUGIA fulvestrant 250 mg/5 mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

fulvestrant eugia fulvestrant 250 mg/5 ml solution for injection pre-filled syringe

eugia pharma (australia) pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: benzyl alcohol; ethanol; benzyl benzoate; castor oil - fulvestrant eugia is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

AZACITIDINE EUGIA azacitidine 100 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

azacitidine eugia azacitidine 100 mg powder for injection vial

eugia pharma (australia) pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine eugia is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

BORTEZOMIB EUGIA bortezomib 3.5 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

bortezomib eugia bortezomib 3.5 mg powder for injection vial

eugia pharma (australia) pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol - bortezomib eugia, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib eugia, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib eugia is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib eugia in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

PLERIXAFOR EUGIA plerixafor 24 mg/ 1.2 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

plerixafor eugia plerixafor 24 mg/ 1.2 ml solution for injection vial

eugia pharma (australia) pty ltd - plerixafor, quantity: 24 mg - injection - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; hydrochloric acid - plerixafor eugia is indicated in combination with granulocyte-colony stimulating factor (g-csf) to mobilise haematopoietic stem cells (hscs) to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma (mm).

VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP POWDER FOR SOLUTION Canada - English - Health Canada

vancomycin hydrochloride for injection, usp powder for solution

eugia pharma inc. - vancomycin (vancomycin hydrochloride) - powder for solution - 500mg - vancomycin (vancomycin hydrochloride) 500mg

VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP POWDER FOR SOLUTION Canada - English - Health Canada

vancomycin hydrochloride for injection, usp powder for solution

eugia pharma inc. - vancomycin (vancomycin hydrochloride) - powder for solution - 1g - vancomycin (vancomycin hydrochloride) 1g